---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-200673"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:17:19.234846+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Forte Biosciences Q2 net loss $(0.27)/share; FB102 phase 1 done, celiac study starts

## Summary
- Net loss per share $(0.27) for Q2 2024 vs $(0.42) for Q2 2023; six-month loss $(0.43) vs $(0.74).
- Cash and equivalents $24.5M; operating expenses $12.8M (Q2 2024) vs $9.0M (Q2 2023).
- FB102 phase 1 SAD/MAD healthy volunteer study completed with good safety and NK cell reduction.
- Forte to initiate celiac disease patient study in Q3 2024; top-line data expected Q2 2025.
- G&A expenses surged to $7.1M (Q2 2024) from $1.9M, driven by legal and professional costs.

## SEC filing metadata
- accession: 0001193125-24-200673
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312524200673/0001193125-24-200673-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312524200673/d886471d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-200673
- JSON: https://secwatch.observer/filing/0001193125-24-200673.json
- Plain text: https://secwatch.observer/filing/0001193125-24-200673.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.